Arrowhead Pharmaceuticals price to sales ratio ARWR

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026: 12.2×
10-year median: 21.3×
Against its 10-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.8× to 157×
Peer median: 5.8×

Arrowhead Pharmaceuticals' price to sales ratio is 12.2× as of Oct 23, 2026.

That is below its ten-year median of 21.3×, lower than on 77% of days in the last ten years.

Over that time it ranged from 3.8× in May 2025 to 157× in Aug 2024.

The median for 10 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

median 21.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.2×	7.1×	19.4×
2025	11.5×	3.8×	11.5×
2024	117×	14.3×	157×
2023	13.7×	9.5×	16.3×
2022	17.7×	11.7×	44.6×
2021	50.1×	50.1×	118×
2020	89.6×	16.2×	98.3×
2019	36.8×	18.8×	85.0×
2018	68.2×	11.6×	128×
2017	8.8×	6.1×	37.0×
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	196×	107×	196×

Against its peers

Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
ARWRArrowhead Pharmaceuticals	12.2×
TGTXTG Therapeutics	10.4×
PTGXProtagonist Therapeutics	31.8×
ALKSAlkermes plc.	4.4×
CORTCorcept Therapeutics	11.2×
AMRXAmneal Pharmaceuticals	2.1×
BMRNBiomarin Pharmaceutical	3.2×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
JAZZJazz Pharmaceuticals	3.0×
INDVIndivior Pharmaceuticals	3.1×
Peer median	5.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Arrowhead Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.